Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on July 12, 2018. The report details corporate governance actions taken at a special meeting of stockholders held on July 12, 2018, in Bridgewater, New Jersey, and the subsequent amendment to the company's Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure changes and stockholder voting results.
Material Changes
- Reverse Stock Split: The company amended its Certificate of Incorporation to effect a 1-for-10 reverse split of its common stock, effective at the close of business on July 16, 2018.
- Share Count: Immediately following the reverse split, approximately 1,800,429 shares of common stock will be outstanding.
- Adjustments: The number of shares issuable upon exercise or conversion of outstanding options and warrants, along with their associated prices, will be adjusted accordingly. Stockholders will receive cash in lieu of fractional shares.
- Voting Results: Of the 14,836,225 shares present at the meeting, 10,733,121 voted for, 3,142,567 voted against, and 960,537 abstained on the proposal to approve the reverse split ratio between 1:5 and 1:10. The proposal was approved.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure of the reverse split mechanics. The company issued a press release on July 13, 2018, announcing the reverse split, which is incorporated by reference.
Investor Verification Checklist
- Verify the effective date of the 1-for-10 reverse split (July 16, 2018).
- Confirm the adjusted share count of approximately 1,800,429 shares post-split.
- Review the treatment of fractional shares (cash payment in lieu of issuance).
- Check for adjustments to outstanding options and warrants exercise prices and share counts.
- Confirm the final vote tally: 10,733,121 For, 3,142,567 Against, 960,537 Abstain.